Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations.

被引：0
|
作者：
Jiang, Di Maria
Jang, Raymond Woo-Jun
Chan, Kelvin K.
Liu, Geoffrey
Amir, Eitan
Elimova, Elena
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[5] Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.6619
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6619
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs
    Sang, Angela
    Zhuo, Selena
    Bochanis, Adara
    Manautou, Jose E.
    Bahal, Raman
    Zhong, Xiao-bo
    Rasmussen, Theodore P.
    BIODRUGS, 2024, 38 (04) : 511 - 526
  • [32] Correction to: A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
    Gizem Kayki-Mutlu
    Zinnet Sevval Aksoyalp
    Leszek Wojnowski
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 383 - 383
  • [33] Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2017
    Yu, Jingjing
    Petrie, Ichiko D.
    Levy, Rene H.
    Ragueneau-Majlessi, Isabelle
    DRUG METABOLISM AND DISPOSITION, 2019, 47 (02) : 135 - 144
  • [34] An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate
    Chen, Emerson Y.
    Raghunathan, Vikram
    Prasad, Vinay
    JAMA INTERNAL MEDICINE, 2019, 179 (07) : 915 - 921
  • [35] US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)
    Naseer, Shabnam
    Weinstein, Edward A.
    Rubin, Daniel B.
    Suvarna, Kalavati
    Wei, Xiaohui
    Higgins, Karen
    Goodwin, Avery
    Jang, Seong H.
    Iarikov, Dmitri
    Farley, John
    Nambiar, Sumathi
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (12) : E1103 - E1111
  • [36] Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
    Fei Liang
    Sheng Zhang
    Qin Wang
    Wenfeng Li
    BMC Cancer, 20
  • [37] Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
    Liang, Fei
    Zhang, Sheng
    Wang, Qin
    Li, Wenfeng
    BMC CANCER, 2020, 20 (01)
  • [38] Update on Novel Drugs for Primary Care Practice: Drugs Approved by the US Food and Drug Administration in 2015
    Smetana, Gerald W.
    ANNALS OF INTERNAL MEDICINE, 2016, 164 (09) : W48 - W54
  • [39] Estimated cost efficacy of US Food and Drug Administration-approved treatments for acne
    Tassavor, Michael
    Payette, Michael J.
    DERMATOLOGIC THERAPY, 2019, 32 (01)
  • [40] Role of US military research programs in the development of US Food and Drug Administration - Approved antimalarial drugs
    Kitchen, LW
    Vaughn, DW
    Skillman, DR
    CLINICAL INFECTIOUS DISEASES, 2006, 43 (01) : 67 - 71
12345